# Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection

> **NCT06999603** · PHASE2 · RECRUITING · sponsor: **Synairgen Research Ltd.** · enrollment: 550 (estimated)

## Conditions studied

- Viral Pneumonia

## Interventions

- **DRUG:** SNG001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06999603
- **Lead sponsor:** Synairgen Research Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-02
- **Primary completion:** 2027-04
- **Final completion:** 2027-05
- **Target enrollment:** 550 (ESTIMATED)
- **Last updated:** 2025-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06999603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06999603, "Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06999603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*